Baltimore biotechs are teaming up in the fight against the Lassa virus.
Profectus Biosciences and Emergent Biosolutions will receive $36 million over five yearesin funding from the Oslo, Norway–based Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against the rat-borne virus. There is currently no vaccine for Lassa virus, which officials said is a threat to public health in West Africa. CEPI announced the deal Thursday.
Our CEO Richard Hatchett highlights the public health threat posed by Lassa virus. This is why we are partnering with Profectus BioSciences, @emergentbiosolu, and @PATHTweets to create a vaccine against this disease. Find out more: https://t.co/9WKEWU7MbS #OutsmartEpidemics pic.twitter.com/L5PRxxb4U1
— CEPI (@CEPIvaccines) August 16, 2018
Profectus, located off Dundalk Ave., will receive $4.3 million in Phase 1 to develop its Lassa vaccine. We’ve previously covered the company’s involvement in efforts to develop a vaccine for Ebola. Gaithersburg-based Emergent Biosolutions, a publicly-traded biopharmaceutical company with expanding manufacturing operations in the city, will provide technical and manufacturing assistance as part of the deal. In a release, Emergent specifically said its Center for Innovation in Advanced Development and Manufacturing in Bayview was designed to handle an increase in manufacturing during public health emergencies.
In turn, Profectus and Emergent have their own agreement that gives Emergent an exclusive option to license and continue to develop the vaccine.
While 80 percent of people who become infected show no symptoms, Nigeria is facing its largest-ever outbreak of the disease, which has resulted in 121 deaths. Outbreaks have also been reported in Liberia, Nigeria, Sierra Leone and South Sudan, according to CEPI.
The companies seem to have a Baltimore-centered partnership budding, as they also received a $25M grant from CEPI to develop a vaccine for Nipah virus earlier this year.
Before you go...
Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.
3 ways to support our work:- Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
- Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
- Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
